Splicing, Signaling, and Survival: The Role of RBM39 in Cholangiocarcinoma Progression.
作者信息
Xu Meng, Calvisi Diego F, Chen Xin
机构信息
Department of General Surgery, The Second Affiliated Hospital of Xi'an JiaoTong University, Xi'an, People's Republic of China.
Institute of Pathology, University of Regensburg, Regensburg, Germany.
出版信息
Cell Mol Gastroenterol Hepatol. 2025;19(1):101419. doi: 10.1016/j.jcmgh.2024.101419. Epub 2024 Oct 28.
Abstract
摘要
相似文献
1
Splicing, Signaling, and Survival: The Role of RBM39 in Cholangiocarcinoma Progression.剪接、信号传导与生存：RBM39在胆管癌进展中的作用
Cell Mol Gastroenterol Hepatol. 2025;19(1):101419. doi: 10.1016/j.jcmgh.2024.101419. Epub 2024 Oct 28.
2
RBM39 Enhances Cholangiocarcinoma Growth Through EZH2-mediated WNT7B/β-catenin Pathway.RBM39通过EZH2介导的WNT7B/β-连环蛋白信号通路促进胆管癌生长。
Cell Mol Gastroenterol Hepatol. 2025;19(1):101404. doi: 10.1016/j.jcmgh.2024.101404. Epub 2024 Sep 14.
3
RNA-binding motif protein RBM39 enhances the proliferation of gastric cancer cells by facilitating an oncogenic splicing switch in MRPL33.RNA结合基序蛋白RBM39通过促进MRPL33中的致癌剪接转换来增强胃癌细胞的增殖。
Acta Pharmacol Sin. 2025 Apr;46(4):1068-1081. doi: 10.1038/s41401-024-01431-4. Epub 2025 Jan 3.
4
Targeting RBM39 through indisulam induced mis-splicing of mRNA to exert anti-cancer effects in T-cell acute lymphoblastic leukemia.通过诱导 mRNA 错误剪接靶向 RBM39，发挥依地司明在 T 细胞急性淋巴细胞白血病中的抗癌作用。
J Exp Clin Cancer Res. 2024 Jul 24;43(1):205. doi: 10.1186/s13046-024-03130-8.
5
Global regulation of alternative RNA splicing by the SR-rich protein RBM39.富含SR的蛋白质RBM39对可变RNA剪接的全局调控。
Biochim Biophys Acta. 2016 Aug;1859(8):1014-24. doi: 10.1016/j.bbagrm.2016.06.007. Epub 2016 Jun 21.
6
UHM-ULM interactions in the RBM39-U2AF65 splicing-factor complex.RBM39-U2AF65剪接因子复合物中的UHM-ULM相互作用。
Acta Crystallogr D Struct Biol. 2016 Apr;72(Pt 4):497-511. doi: 10.1107/S2059798316001248. Epub 2016 Mar 24.
7
The RBM39 degrader indisulam inhibits acute megakaryoblastic leukemia by altering the alternative splicing of ZMYND8.RBM39降解剂茚地西胺通过改变ZMYND8的可变剪接来抑制急性巨核细胞白血病。
Cell Biosci. 2025 Apr 13;15(1):46. doi: 10.1186/s13578-025-01380-3.
8
RBM39 promotes hepatocarcinogenesis by regulating RFX1's alternative splicing and subsequent activation of integrin signaling pathway.RBM39通过调节RFX1的可变剪接及随后整合素信号通路的激活来促进肝癌发生。
Oncogene. 2025 Jun;44(20):1488-1503. doi: 10.1038/s41388-025-03327-x. Epub 2025 Mar 3.
9
Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma.靶向RBM39-MEK5轴与硼替佐米协同作用，抑制多发性骨髓瘤的恶性生长。
Blood Adv. 2025 Apr 22;9(8):1991-2005. doi: 10.1182/bloodadvances.2025015815.
10
YAP/TAZ interacts with RBM39 to confer resistance against indisulam.YAP/TAZ与RBM39相互作用以赋予对茚地那韦的抗性。
Oncogenesis. 2024 Jul 15;13(1):25. doi: 10.1038/s41389-024-00527-0.
本文引用的文献
1
RBM39 Enhances Cholangiocarcinoma Growth Through EZH2-mediated WNT7B/β-catenin Pathway.RBM39通过EZH2介导的WNT7B/β-连环蛋白信号通路促进胆管癌生长。
Cell Mol Gastroenterol Hepatol. 2025;19(1):101404. doi: 10.1016/j.jcmgh.2024.101404. Epub 2024 Sep 14.
2
The Recent Trends of Systemic Treatments and Locoregional Therapies for Cholangiocarcinoma.胆管癌全身治疗和局部区域治疗的最新趋势
Pharmaceuticals (Basel). 2024 Jul 8;17(7):910. doi: 10.3390/ph17070910.
3
Pharmacology and pharmacokinetics of tazemetostat.他美替尼的药理学和药代动力学。
Cancer Chemother Pharmacol. 2024 May;93(5):509-517. doi: 10.1007/s00280-024-04658-4. Epub 2024 Mar 23.
4
Emerging Therapies in Management of Cholangiocarcinoma.胆管癌治疗的新兴疗法
Cancers (Basel). 2024 Jan 31;16(3):613. doi: 10.3390/cancers16030613.
5
β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.β-连环蛋白维持 YES 相关蛋白癌基因活性并对其有需求作用在胆管细胞癌中。
Gastroenterology. 2022 Aug;163(2):481-494. doi: 10.1053/j.gastro.2022.04.028. Epub 2022 Apr 27.
6
RNA-binding protein 39: a promising therapeutic target for cancer.RNA结合蛋白39：一种有前景的癌症治疗靶点。
Cell Death Discov. 2021 Aug 13;7(1):214. doi: 10.1038/s41420-021-00598-7.
7
RNA-binding motif protein 39 (RBM39): An emerging cancer target.RNA结合基序蛋白39（RBM39）：一个新兴的癌症靶点。
Br J Pharmacol. 2022 Jun;179(12):2795-2812. doi: 10.1111/bph.15331. Epub 2021 Jan 3.
8
Cholangiocarcinoma 2020: the next horizon in mechanisms and management.胆管癌 2020：机制和管理的新前沿。
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588. doi: 10.1038/s41575-020-0310-z. Epub 2020 Jun 30.
Zotero 插件